This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

EU watchdog gives new ALS treatment thumbs up

EU
Credit: CC0 Public Domain

Europe's medicines watchdog gave the green light Friday to a new treatment for a rare form of the neurodegenerative disease ALS, saying it should reduce the symptoms of the deadly illness.

Amyotrophic lateral sclerosis, sometimes called Lou Gehrig's disease after the famous baseball player, devastates nerve cells in the brain and . The mean survival time with ALS is two to five years.

Sold under the brand name "Qalsody", the medicine toferson is aimed at adults suffering from ALS as the result of a genetic mutation, the European Medicines Agency said.

"The exact causes of ALS are unknown but are believed to include genetic and ," the Amsterdam-based EMA said.

"In approximately 2.0 percent of people living with ALS, the condition is caused by a genetic mutation (change) that leads to the production of defective SOD1 enzymes, causing to die," it said.

Qalsody reduces the production of the SOD1 protein and is therefore "expected to improve the symptoms of ALS."

To date, there is no effective neuroprotective treatment for all ALS patients.

Despite the progress made in recent years, the disease currently remains incurable.

There is only one other treatment for ALS, called "Riluzole", authorised in the EU.

Patients are also offered supportive treatment to relieve the symptoms of the disease, such as physical, occupational or speech therapy and breathing support.

"There is a large unmet medical need for effective therapies that preserve muscle function and prolong the life of patients with ALS," the EMA said.

© 2024 AFP

Citation: EU watchdog gives new ALS treatment thumbs up (2024, February 23) retrieved 18 April 2024 from https://medicalxpress.com/news/2024-02-eu-watchdog-als-treatment-thumbs.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA approves drug for rare form of ALS

1 shares

Feedback to editors